Peptonic Medical AB (publ) announced the appointment of Jenni Björnulfson as the company's new Chief Financial Officer (CFO). Jenni will assume the position on September 1, 2024, replacing Albert Lindgren. During the transition period until Jenni assumes office, Daniel Rudeklint will serve as Acting CFO.

Jenni joins Peptonic from Lidds AB, where she has served as CFO since 2021 and assumed the role of CEO in December 2023. Previous roles include CFO for Promore Pharma and Cinclus Pharma, alongside positions as a stock analyst at ABG Sundal Collier and in corporate finance at Alfred Berg and Handelsbanken. Jenni holds a master's degree from the Stockholm School of Economics and has undertaken studies at the Karolinska Institute.

During the transition period, Daniel Rudeklint will undertake the role of Acting CFO. Daniel, currently a board member of Peptonic, possesses a deep understanding of the company's operations. With experience as both CEO and CFO, as well as holding board positions in both listed and unlisted companies, Daniel brings invaluable expertise to his interim role.